secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093933
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports Q2 net loss of $57.9M; cash $850.6M; Phase 3 epilepsy data H2 2025
--------------------------------------------------------------------------------

- Net loss for Q2 2024 was $57.9M, compared to $47.5M in Q2 2023.
- Cash and marketable securities $850.6M as of June 30, 2024, down from $930.9M at Dec 31, 2023; cash runway into 2027.
- Phase 3 X-TOLE2 top-line FOS data anticipated H2 2025; MDD Phase 3 study to start H2 2024.
- R&D expenses $49.7M (Q2 2024) vs $44.0M (Q2 2023); G&A $19.4M vs $11.6M.
- Pre-clinical Kv7 and Nav1.7 candidates advancing; multiple INDs expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024093933/0000950170-24-093933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024093933/xene-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer